It has been 30 years since Holzman introduced a special issue of the Schizophrenia Bulletin entitled “Thought Disorder in Schizophrenia.” He pointed out in his Editor’s Introduction that in contrast to the explosion of interest at that time in the biological aspects of schizophrenia, there were important areas of study that represented “... relatively neglected aspects of the psychopathology of schizophrenia, namely the varieties of thinking disorders (emphasis added) characteristic of schizophrenic patients and their possible underlying mechanisms.” Perhaps presciently, he ended his introduction by expressing hope that the articles included in that issue would lead to further intensive study of the cognitive (emphasis added) dysfunctions in schizophrenia. There has, indeed, been extensive research conducted in further understanding cognitive dysfunctions in schizophrenia, but considerably less so in understanding thought disorder.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464106 | PMC |
http://dx.doi.org/10.1093/schbul/sbx003 | DOI Listing |
BMC Res Notes
January 2025
Department of Anatomy and Neuroscience, Institute of Medicine, University of Tsukuba, 1-1- 1, Tennodai, Tsukuba, Ibaraki, 305-8577, Japan.
Objective: Reactivity of microglia, the resident cells of the brain, underlies innate immune mechanisms (e.g., injury repair), and disruption of microglial reactivity has been shown to facilitate psychiatric disorder dysfunctions.
View Article and Find Full Text PDFRMD Open
January 2025
Rheumatology Department, IRCCS Galeazzi - Sant'Ambrogio Hospital, Milan, Italy
Objectives: The Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) has developed a calcium pyrophosphate deposition (CPPD) nomenclature project. This systematic literature review constituted its first step and aimed to provide a state-of-the-art analysis of the medical literature of the last 20 years.
Methods: A systematic literature search was undertaken in the , and databases between 2000 and 2022, restricted to studies on humans and in the English language.
BMJ Open Respir Res
January 2025
Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
Background: Cystic fibrosis (CF) is associated with a historically high treatment burden which causes anxiety and exhaustion for parents of children with CF, especially in the early years of a child's life. Recently, a new medication, elexacaftor/tezacaftor/ivacaftor (ETI), has become available to some people with CF, which has had a significant impact on the quality of life of older children and adults. This medication will soon be available for children ages 2-5 in the UK.
View Article and Find Full Text PDFTuberculosis (Edinb)
January 2025
Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa. Electronic address:
In recent years, a rise in non-tuberculosis mycobacteria pulmonary disease (NTM-PD) has been reported in several countries. However, data for high-burden tuberculosis settings, including South Africa, is currently limited. In this study, we conducted a retrospective analysis of routine diagnostic data obtained from one diagnostic laboratory in South Africa between 2015 and 2019.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
February 2025
Zanvyl Krieger Mind/Brain Institute, Johns Hopkins University, Baltimore, MD 21218.
The hippocampal dentate gyrus (DG) is thought to orthogonalize inputs from the entorhinal cortex (pattern separation) and relay this information to the CA3 region. In turn, attractor dynamics in CA3 perform a pattern completion or error correction operation before sending its output to CA1. In a mouse model of congenital hypoplasia of the DG, a deficiency in the (Wls) gene, specifically in cells expressing , which targets neuronal progenitors, led to an almost total absence of dentate granule cells and modestly impaired performance in spatial tasks.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!